Beisol Pharma Tienen
ActiveBeisol Pharma Tienen has been active since 2014 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show negative equity (€-52k) and a net result of €3k. Equity is shrinking by ~57.1% per year across the filed fiscal years. Its solvency ranks better than 14% of 1517 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 1.1% (low).
Checked score
Score 2025
33
/ 100
Weak
The score weighs solvency, liquidity and profitability. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability43▼-28
Solvency0=
Growth38▲+14
Track record100
Bankruptcy probability, 12 months
1.1%
Low
0%0.5%1.5%4%10%≥ 25%
No credit on open account
Liquidity short (current ratio 0.71 against 0.71 in 2024; short-term debt: 141% and cash: 0.2% of total assets), and equity is negative.
Credit advice for your own amount and term
Signals
Seven signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 77
Relative position
BE, all sectors
reference
Sector 77
higher
← fewer bankruptcies
more bankruptcies →
raises risk · Annual accounts: weaker financial profile
The latest annual accounts show a weaker profile in solvency, result or liquidity than companies that stay afloat.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
-41%
Return on assets
2.1%
Age of the figures
18 mo
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
raises risk · Weak solvency vs sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 14% of 1517 sector peers (2025).
NBB · sector comparisonPosition among 1517 sector peers
Solvency
better than 14%
← weakest
strongest →
neutral · Latest accounts filed on time
The financial year that closed on 31-03-2025 was due by 31-10-2025 and was filed on 21-10-2025, 10 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
10 d early
2024
16 d early
2023
8 d early
2022
14 d early
2021
29 d early
2020
15 d late
2019
24 d early
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-03-2026 and is due by 31-10-2026. Nothing is late today.
Companies Code · seven monthsPosition in the running window
31-03-2026 close23-09-2026 today31-10-2026 deadline
Financials · fiscal year 2025, micro schema
Turnover
€11k▼ 55.6%
2024 · €25k
2019: €37k
2020: €38k
2021: €25k
2022: €21k
2023: €25k
2024: €25k
2019 → 2025
EBIT margin
24.1%▲ 75.5pp
2024 · -51.4%
2019: 7.5%
2020: -2.6%
2021: -43.9%
2022: -68.4%
2023: -68.0%
2024: -51.4%
2019 → 2025
Net result
€3k
2024 · €-13k
2019: €-510
2020: €-3k
2021: €-14k
2022: €-15k
2023: €-19k
2024: €-13k
2019 → 2025
Working capital
€-52k▲ 4.9%
2024 · €-54k
2019: €-96k
2020: €-89k
2021: €-93k
2022: €-79k
2023: €-70k
2024: €-54k
2019 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Turnover€25k-€21k▼ 15.4%€25k▲ 19.1%€25k=€11k▼ 55.6%
Equity€-7k-€-22k▼ 207%€-41k▼ 84.5%€-54k▼ 31.3%€-52k▲ 4.9%
Operating result€-11k-€-14k▼ 31.9%€-17k▼ 18.6%€-13k▲ 24.5%€3k
Net result€-14k-€-15k▼ 7.8%€-19k▼ 25.2%€-13k▲ 31.7%€3k
Turnover and EBIT margin not published: the abbreviated or micro schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result returns to profit in 2025: €3k after a loss of €13k in 2024, the highest result in the available series.
Key figures and ratios
Solvency
-41.0%▼
2024 · -40.8%
Current ratio
0.71▼
2024 · 0.71
Quick ratio
0.12▼
2024 · 0.15
Debt / equity
-3.44▲
2024 · -3.45
ROA
2.1%▲
2024 · -9.7%
Debt
€178k▼
2024 · €188k
Debt ≤ 1 year
€178k▼
2024 · €188k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€134k€126k▼
Intangible fixed assets21€0-
Tangible fixed assets22/27€0-
Current assets29/58€134k€126k▼
Stocks and contracts in progress3€106k€106k=
Stocks30/36€106k€106k=
Amounts receivable within one year40/41€28k€21k▼
Trade receivables40€25k€20k▼
Other amounts receivable41€3k€923▼
Cash at bank and in hand54/58€12€243▲
Equity and liabilities
Total equity and liabilities10/49€134k€126k▼
Equity10/15€-54k€-52k▲
Contributions10/11€6k€6k=
Capital10€6k€6k=
Issued capital100€19k€19k=
Uncalled capital101€12k€12k=
Reserves13€4k€4k=
Non-distributable reserves130/1€201€201=
Legal reserve130€201€201=
Distributable reserves133€4k€4k=
Profit (loss) carried forward14€-65k€-62k▲
Amounts payable17/49€188k€178k▼
Amounts payable within one year42/48€188k€178k▼
Trade debts44€8k€11k▲
Suppliers440/4€8k€11k▲
Other amounts payable47/48€180k€168k▼
Income statement
Code20242025
Turnover70€25k€11k▼
Goods, raw materials, services and sundry goods60/61€9k€8k▼
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€28k-
Other operating charges640/8€384€387▲
Gross operating margin9900€16k€3k▼
Operating profit (loss)9901€-13k€3k▲
Financial charges65/66B€35€30▼
Recurring financial charges65€35€30▼
Profit (loss) for the period before taxes9903€-13k€3k▲
Profit (loss) for the period9904€-13k€3k▲
Profit (loss) for the period to be appropriated9905€-13k€3k▲
Appropriation of the result
Profit (loss) to be appropriated9906€-65k€-62k▲
Profit (loss) brought forward from the previous period14P€-52k€-65k▼
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2025
21-10
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema
31-03
Financial
Back to profitnet €3k
Net result €3k after 6 loss-making years.
2024
15-10
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema
2023
23-10
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema
31-03
Financial
Weakest financial yearnet €-19k
Net result drops to €-19k, the lowest in the series; recovery starts the following year.
2022
17-10
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema
2021
02-10
NBB filing
Annual accounts filed
fiscal year 2021 · micro schema
2020
15-11
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema · 15 days late
2019
07-10
NBB filing
Annual accounts filed
fiscal year 2019 · abbreviated schema
2018
06-09
NBB filing
Annual accounts filed
fiscal year 2018 · abbreviated schema
2017
06-11
NBB filing
Annual accounts filed
fiscal year 2017 · abbreviated schema · 6 days late
2016
13-09
NBB filing
Annual accounts filed
fiscal year 2016 · abbreviated schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
1 act for this company is in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Lubbeek · 1 establishment unit since 2014
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Staatsbaan(LUB) 1873210 LubbeekGround area
1,002 m²
Building footprint
263 m²
Volume, LiDAR
2,293 m³
Parcel 24066H0017/00G004, Flanders · tallest building 12.5 m, ±3 floors. Linked by address, not a title deed.
1 establishment unit
beisol pharma tienen
since 20142.226.766.741
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 24066H0017/00G004 | Flanders | 1,002 m² | 1 · 263 m² | 12.5 m · 3 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
LeBonBail
BE 0597.636.497
Beauvechain · Eq €6k
MedTec
BE 0732.512.821
Gent · Eq €6k
Beisol Pharma Poederlee
BE 0544.651.040
Lubbeek · Eq €6k
POLYCLICK
BE 0777.535.172
De Panne · Eq €8k
Quinconce 10
BE 1001.926.559
La Louvière · Eq €6k
Of 421 companies in sector 77400 we hold annual accounts for 152. 60 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company (pre-2019)
Founded22-01-2014
Fiscal year end31-03
Activities, NACEBEL
77400Rental and leasing activities
Sources
Crossroads Bank for EnterprisesNational Bank · 11 filingsAddress and cadastre registers
Data from official sources, last processed on 22-09-2026. Scores and ratios are computed by Checked and are not a credit decision.
Contact details
3 entriesE-mail:theo@craynwinkel.be
Phone:016622141
Fax:016620609